<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Hepatitis C virus infection in patients on maintenance dialysis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Hepatitis C virus infection in patients on maintenance dialysis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Hepatitis C virus infection in patients on maintenance dialysis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Marion Muche, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Seema Baid-Agrawal, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Steve J Schwab, MD, FACP, FASN</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Adrian M Di Bisceglie, MD</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Eric N Taylor, MD, MSc, FASN</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Allyson Bloom, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 14, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Hepatitis C virus (HCV) infection is common and associated with significant morbidity and mortality among patients on dialysis.</p><p>This topic reviews HCV infection among patients on dialysis, including epidemiology, screening, and prevention.</p><p>The treatment of HCV infection among patients with reduced kidney function, including those on dialysis, is discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/93448.html" rel="external">"Treatment of chronic hepatitis C infection in adults with kidney function impairment"</a>.)</p><p>General issues related to HCV infection among transplant kidney donors and recipients and recurrent or de novo HCV-related kidney disease in transplant recipients are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/7361.html" rel="external">"Hepatitis C virus infection in kidney donors"</a> and  <a class="medical medical_review" href="/d/html/7310.html" rel="external">"Hepatitis C infection in kidney transplant candidates and recipients"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>HCV infection is more common in patients on dialysis than in healthy populations. The Dialysis Outcomes and Practice Patterns Study (DOPPS) reported an overall prevalence of 9.9 percent among adult patients on hemodialysis randomly selected from dialysis facilities in high- and middle-income countries (France, Germany, Italy, Japan, Spain, the United Kingdom, China, Russia, Sweden, Belgium, Turkey, Gulf countries, and the United States) [<a href="#rid1">1</a>]. This is compared with a reported global prevalence of approximately 3 percent in the general population. (See  <a class="medical medical_review" href="/d/html/3675.html" rel="external">"Epidemiology and transmission of hepatitis C virus infection", section on 'Global distribution'</a>.)</p><p>HCV infection is more common among patients on dialysis in resource-limited countries, with an approximate incidence of 4.4 cases in 100 patient-years compared with 1 in 100 patients-years in resource-rich countries [<a href="#rid2">2-19</a>].</p><p>Within individual countries, there is a wide variation in prevalence of HCV in different dialysis units and geographic regions [<a href="#rid4">4,5,20,21</a>]. In 2002, the prevalence of anti-HCV antibodies ranged from 5.5 to 9.8 percent in various geographic regions in the United States [<a href="#rid4">4</a>]. Similarly, the prevalence ranged from 4 to 14 percent in different dialysis centers in Brazil in a 2011 study [<a href="#rid5">5</a>]. A 2021 meta-analysis of patients on dialysis in Africa found an overall prevalence of anti-HCV antibodies of 23 percent, ranging from 2.3 (Nigeria) to 60.9 percent (Egypt) [<a href="#rid22">22</a>].</p><p>HCV infection is declining among patients on dialysis. A meta-analysis including 407 international studies that were conducted between 1989 and 2021 reported an association between later publication year and lower prevalence of HCV in patients on hemodialysis [<a href="#rid23">23</a>]. Among member nations in the European Dialysis and Transplant Association (EDTA), the prevalence of anti-HCV antibodies declined from 21 percent in 1992 to 12.5 percent in 1999 [<a href="#rid24">24-26</a>], and subsequent studies have suggested an ongoing decline [<a href="#rid1">1,8,27,28</a>]. This decline reflects the reduction in use of blood transfusions, ability to screen blood products for HCV, and the implementation of infection control measures within dialysis units.</p><p>Nonetheless, outbreaks still occur [<a href="#rid29">29</a>], and the relatively high incidence of anti-HCV antibodies in hemodialysis units is a cause for concern, especially in resource-limited countries [<a href="#rid17">17,30</a>].</p><p class="headingAnchor" id="H314465823"><span class="h1">RISK FACTORS</span><span class="headingEndMark"> — </span>The following dialysis-specific risk factors have been identified for HCV infection:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dialysis vintage</strong> – Among patients on hemodialysis, the risk of seroconversion increases with time on dialysis, particularly after five years [<a href="#rid31">31,32</a>]. By contrast, time on peritoneal dialysis does not appear to be a risk factor [<a href="#rid33">33</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mode of dialysis </strong>–<strong> </strong>Patients on peritoneal dialysis are at lower risk for HCV infection compared with patients on hemodialysis [<a href="#rid33">33-35</a>]. In a group of 129 anti-HCV-negative patients on chronic dialysis, the rate of seroconversion was 0.15 per patient-year on hemodialysis compared with 0.03 per patient-year on continuous ambulatory peritoneal dialysis (CAPD) [<a href="#rid34">34</a>]. In fact, the majority of anti-HCV-positive CAPD patients likely acquired HCV infection while on hemodialysis since patients often switch modalities.</p><p></p><p class="bulletIndent1">Patients on peritoneal dialysis are at lower risk for HCV infection because they have fewer blood transfusions and less parenteral exposure (ie, they do not have an arteriovenous access or require an extracorporeal blood circuit for dialysis). In addition, peritoneal dialysis offers a more isolated environment since it is primarily a home procedure.</p><p></p><p class="bulletIndent1">Patients on home hemodialysis are also at lower risk than those who receive it at a dialysis unit, likely related to their isolated environment [<a href="#rid36">36</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Characteristics of the dialysis unit </strong>–<strong> </strong>Characteristics of individual dialysis units that confer an increased risk of HCV infection include a high prevalence of HCV infection in the unit and the personnel-to-patient ratio [<a href="#rid2">2,37-39</a>].</p><p></p><p class="bulletIndent1">A survey by the Portuguese Society of Nephrology found that, among units with a HCV prevalence of &lt;19 percent, the annual incidence of seroconversion was 2.5 percent [<a href="#rid37">37</a>]. By comparison, among units with a prevalence &gt;60 percent, the annual incidence of seroconversion was 35.3 percent.</p><p></p><p class="bulletIndent1">Among centers with a high prevalence of patients with HCV infection, the risk of infection may be increased in centers with a low personnel-to-patient ratio [<a href="#rid39">39</a>]. The risk is also higher among patients who are dialyzed in close proximity to patients with HCV infection [<a href="#rid37">37,38</a>].</p><p></p><p class="bulletIndent1">These observations suggest that nosocomial infection contributes to the high prevalence of HCV infection among patients on hemodialysis. Nosocomial transmission of HCV is proven by studies that demonstrated by viral gene sequence analysis that the same viral strain predominated within individual facilities [<a href="#rid40">40-44</a>]. HCV genotyping of 23 seroconverters in a Belgian hemodialysis unit revealed that 20 were infected with exactly the same HCV strain [<a href="#rid40">40</a>]. Because parts of the HCV genome are extremely variable between strains, these studies provide proof of routes of infection.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>The number of blood transfusions</strong> – In earlier studies, HCV seropositivity was associated with receiving a higher number of units of blood products [<a href="#rid31">31</a>]. However, the risk of acquiring posttransfusion HCV infection has declined. In particular, in locations where the blood supply is screened with HCV nucleic acid testing as well as antibody testing, as in resource-rich settings, the risk of HCV infection from transfusion is virtually nonexistent. However, in countries where HCV screening is performed with antibody testing only, blood transfusion can still be a risk factor for HCV infection [<a href="#rid32">32</a>]. Overall, the decreased risk associated with transfusion is due both to HCV screening of blood products and to the decreased use of blood transfusion to treat anemia since the introduction of erythropoietin. (See  <a class="medical medical_review" href="/d/html/1926.html" rel="external">"Treatment of anemia in patients on dialysis", section on 'Erythropoiesis-stimulating agents (ESAs)'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other factors</strong> – Other risk factors include a history of organ transplantation or injection drug use [<a href="#rid32">32,34,45-48</a>]. A history of previous organ transplantation may reflect transmission from the organ donor [<a href="#rid34">34</a>].</p><p></p><p class="bulletIndent1">A history of injection drug use was present in 30 percent of anti-HCV antibody-positive patients receiving hemodialysis at the Northwest Kidney Center, Seattle [<a href="#rid46">46</a>] and in 73 percent in two urban hemodialysis units in Miami [<a href="#rid47">47</a>]. (See  <a class="medical medical_review" href="/d/html/3675.html" rel="external">"Epidemiology and transmission of hepatitis C virus infection"</a>.)</p><p></p><p class="headingAnchor" id="H3463442916"><span class="h1">PREVENTION</span><span class="headingEndMark"> — </span>Our approach to the prevention of nosocomial HCV infection within hemodialysis units is consistent with the 2022 Kidney Disease: Improving Global Outcomes (KDIGO) clinical practice guidelines and with recommendations from the Centers for Disease Control and Prevention (CDC) in the United States [<a href="#rid49">49,50</a>]. Measures are discussed here.</p><p class="headingAnchor" id="H107946468"><span class="h2">Standard infection control practices and universal precautions</span><span class="headingEndMark"> — </span>Hemodialysis units should implement and adhere to strict procedures (including universal precautions) aimed at preventing transmission of bloodborne pathogens  (<a class="graphic graphic_table graphicRef97603" href="/d/graphic/97603.html" rel="external">table 1</a>). The enforcement of universal precautions has been shown to prevent transmission of HCV in hemodialysis units [<a href="#rid51">51</a>].</p><p>As noted above, the major underlying reason for nosocomial HCV infection within hemodialysis units is a breakdown in standard infection control practices [<a href="#rid29">29,52-55</a>] (see <a class="local">'Risk factors'</a> above). Several outbreaks of HCV infection in hemodialysis units have been associated with a failure to rigidly enforce universal precautions and standard infection control measures [<a href="#rid53">53-55</a>]. Such infractions of standard practice included sharing of a multidose heparin vial between patients with and without HCV infection and failure to change gloves between patients while performing hemodialysis treatments [<a href="#rid53">53-55</a>]. Also suggesting a breakdown in universal precautions, HCV RNA has been detected on the hands of some dialysis personnel despite apparent adherence to standard precautions [<a href="#rid56">56</a>].</p><p>Rigorous infection control measures, cleaning and disinfection of all instruments and environmental surfaces that are routinely touched, and a ban on sharing of articles between patients have resulted in a decline in the incidence of HCV infection [<a href="#rid57">57,58</a>]. Hygienic precautions that prevent the transfer between patients of blood or fluids contaminated with blood are shown in the table  (<a class="graphic graphic_table graphicRef97604" href="/d/graphic/97604.html" rel="external">table 2</a>). Separate rooms should be used, if possible, for reprocessing and storage of dialyzers from patients with HCV infection.</p><p>The peritoneal fluid of patients with HCV infection on peritoneal dialysis is a potential infectious risk. HCV RNA has been demonstrated in the continuous ambulatory peritoneal dialysis (CAPD) effluent [<a href="#rid59">59</a>].</p><p class="headingAnchor" id="H4167484677"><span class="h2">Response to suspected outbreak</span><span class="headingEndMark"> — </span>Any new case of hepatitis C in a patient on dialysis is likely to be a health facility-associated infection and should be reported to <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fhepatitis%2Foutbreaks%2Fhealthcarehepoutbreaktable.htm&amp;token=sReyk%2BNxbeiDDZRQivvqzA4Qfd9fZYLthRmrtf3O7XXe9htOiV5THsBU7gZayx6coY1MpM9FXkE%2B91wTX1YT5pITmb5k2uAddxW%2F1OOeK1g%3D&amp;TOPIC_ID=1861" target="_blank">public health authorities</a>.</p><p>When there is a new case, all patients who have been exposed should be tested for HCV with HCV RNA (see <a class="local">'Screening and diagnosis'</a> below). At minimum, this includes all patients dialyzed in the same shift and ideally includes all patients dialyzed at the same facility.</p><p class="headingAnchor" id="H2928059165"><span class="h2">Practices that provide little or no benefit</span></p><p class="headingAnchor" id="H835571927"><span class="h3">Isolation of patients with HCV infection</span><span class="headingEndMark"> — </span>Patients with HCV infection do not require isolation or the use of dedicated dialysis machines. The risk of virus transmission via the internal pathways of the dialysis machine is very low, provided hygienic precautions for dialysis machines are maintained  (<a class="graphic graphic_table graphicRef97604" href="/d/graphic/97604.html" rel="external">table 2</a>) [<a href="#rid50">50</a>]. (See <a class="local">'Standard infection control practices and universal precautions'</a> above.)</p><p>Although many early reports suggested that sharing dialysis machines increased the risk of HCV infection [<a href="#rid60">60-62</a>] and using dedicated machines and isolated areas along with universal precautions decreased the incidence of seroconversion [<a href="#rid37">37,58,63-65</a>], the decreased risk was likely due to the enforcement of universal precautions rather than the isolation measures. In a multicenter study from Belgium, no new cases of HCV transmission occurred over a 54-month study period, although none of the participating hemodialysis centers used dedicated machines for anti-HCV antibody-positive patients [<a href="#rid51">51</a>]. The decrease in prevalence in this study occurred after universal precautions were instituted. In addition, after adjusting for confounding factors, neither the Dialysis Outcomes and Practice Patterns Study (DOPPS) nor a study from Italy that included 3492 patients showed a decrease in the incidence of HCV seroconversion associated with isolation measures [<a href="#rid2">2,39</a>].</p><p class="headingAnchor" id="H985045484"><span class="h3">Use of specific membranes</span><span class="headingEndMark"> — </span>There is no advantage to using a specific dialysis membrane. To date, a higher prevalence of anti-HCV antibodies among patients on hemodialysis has not been associated with any particular dialysis membrane.</p><p>The passage of HCV through any intact dialyzer membrane is unlikely since the viral particles have an estimated diameter of 35 nm, which is much greater than the pores of even the most permeable dialysis membranes, providing there is no disruption of membrane integrity during filter assembly, during the dialysis session itself, or with dialyzer reuse. This has been demonstrated in several studies that showed that both low-flux (cellulose) and high-flux (cellulose-diacetate, polysulfone, and polyacrylonitrile) dialyzers prevent contamination of the dialysis ultrafiltrate with HCV RNA [<a href="#rid66">66-68</a>].</p><p>Some investigators have detected HCV RNA by polymerase chain reaction (PCR) in the dialysate of apparently intact polyacrylonitrile membranes but not cellulose membranes [<a href="#rid69">69</a>]. However, the detection of HCV RNA in the dialysate by PCR may imply the presence of fragments of viral RNA but not the infective virus itself, which may not lead to transmission of infection.</p><p class="headingAnchor" id="H1236283161"><span class="h3">Avoidance of "reuse"</span><span class="headingEndMark"> — </span>Reuse or reprocessing dialyzers does not appear to increase nosocomial transmission of HCV infection, provided infection control measures are employed [<a href="#rid4">4,37,38,70,71</a>]. We agree with the 2022 KDIGO guidelines that suggest dialyzers may be reused if there is adherence to standard infection control procedures [<a href="#rid50">50</a>]. Separate rooms should be used, if possible, for reprocessing and storage of dialyzers from patients with HCV infection.</p><p>Both surveillance data from the United States CDC and from a prospective study in 15 hemodialysis units in Belgium showed that the incidence of HCV infection in patients treated in units that reprocessed dialyzers was comparable with those that did not, although separate rooms for reprocessing were not used in the majority of units [<a href="#rid4">4,38</a>].</p><p>Similar findings were noted by a Portuguese Society of Nephrology survey [<a href="#rid37">37</a>]. However, in the Portuguese survey, among units that reused dialyzers, the lowest incidence of infection was observed in patients dialyzed in units that used separate rooms to reprocess dialyzers from anti-HCV antibody-positive and anti-HCV antibody-negative patients or that had a ban on reprocessing dialyzers from anti-HCV antibody-positive patients [<a href="#rid37">37</a>]. It remains unclear whether the low rate of infection in centers with dedicated rooms for reprocessing dialyzers from patients with HCV infection reflected a causal relationship or a better adherence to infection control practices.</p><p>By contrast, a 2022 meta-analysis identified dialyzer reuse as a potential risk factor for HCV. However, these findings were based only on four studies and need to be interpreted with caution [<a href="#rid23">23</a>]. </p><p class="headingAnchor" id="H3461288552"><span class="h1">SCREENING AND DIAGNOSIS</span><span class="headingEndMark"> — </span>All patients on dialysis should be screened for HCV infection. Methods of screening and diagnosis include testing for anti-HCV antibodies and testing for HCV RNA. (See  <a class="medical medical_review" href="/d/html/89950.html" rel="external">"Screening and diagnosis of chronic hepatitis C virus infection", section on 'Diagnosis'</a>.)</p><p>Our approach is as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>All patients on hemodialysis should be screened for HCV infection upon initiation of hemodialysis or on transfer from another hemodialysis unit. We generally test concurrently for HCV RNA and anti-HCV antibody. HCV antibody production is commonly absent in end-stage kidney disease (ESKD) patients because of the immunocompromised state. False-negative anti-HCV antibody tests have been reported to be as high as 17.9 percent in dialysis units in countries with high HCV prevalence rates [<a href="#rid72">72</a>]. Thus, HCV RNA testing should be performed in all patients if there is clinical suspicion of infection. However, in low-prevalence regions, many centers still test for anti-HCV antibody first followed by nucleic acid testing if the anti-HCV antibody is positive. In low-prevalence countries, anti-HCV antibody testing may be adequate to rule out HCV infection.</p><p></p><p class="bulletIndent1">Subsequently, patients without evidence of infection should be screened every 6 to 12 months, either by concurrent testing for HCV-RNA and anti-HCV antibody or by testing for anti-HCV antibody followed by a test for HCV RNA if the anti-HCV antibody is positive.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients who develop unexplained, abnormal serum aminotransferase levels should be tested for HCV RNA. However, the frequency of routine serum transaminase testing varies widely (from quarterly to annually) in different dialysis centers. Moreover, the levels of transaminases may be depressed in patients on dialysis and may not reflect the severity of the liver inflammation [<a href="#rid73">73-76</a>] and therefore should not be relied upon for screening for hepatitis. (See  <a class="medical medical_review" href="/d/html/1895.html" rel="external">"Serum enzymes in patients with kidney failure"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients on hemodialysis who travel to resource-limited countries and receive hemodialysis should be tested for HCV RNA at 4, 12, and 24 weeks following their return [<a href="#rid77">77</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If nosocomial infection is suspected, all patients who have been exposed should be tested for HCV RNA at 4, 12, and 24 weeks following potential exposure. At minimum, this includes all patients dialyzed in the same shift and ideally includes all patients dialyzed at the same facility. Such patients should also have serum aminotransferases measured at 4 and 12 weeks and anti-HCV antibody measured at 12 and 24 weeks. (See  <a class="medical medical_review" href="/d/html/3650.html" rel="external">"Clinical manifestations, diagnosis, and treatment of acute hepatitis C virus infection in adults", section on 'Patients with discrete HCV exposure'</a>.)</p><p></p><p class="bulletIndent1">As noted above, any new case of hepatitis C in a patient on dialysis is likely to be health facility associated and should be considered a result of nosocomial infection. (See <a class="local">'Response to suspected outbreak'</a> above.)</p><p></p><p>A positive HCV RNA result is evidence of HCV infection. Patients with positive tests should be evaluated further to determine the extent of liver disease through physical exam, laboratory testing, and consideration of liver biopsy. (See  <a class="medical medical_review" href="/d/html/89950.html" rel="external">"Screening and diagnosis of chronic hepatitis C virus infection", section on 'Additional evaluation'</a>.)</p><p>As direct HCV-RNA testing is expensive and may sometimes not be technically available in resource-poor countries, the quantitative determination of the HCV core antigen (HCVcAg) in the serum or plasma using a monoclonal antibody has been proposed as a cheaper alternative to direct HCV-RNA testing [<a href="#rid78">78</a>]. However, the sensitivity of HCVcAg is considerably lower than that of HCV RNA testing [<a href="#rid79">79</a>]. (See  <a class="medical medical_review" href="/d/html/89950.html" rel="external">"Screening and diagnosis of chronic hepatitis C virus infection", section on 'HCV core antigen test'</a>.)</p><p>Occult HCV infection is defined as the detection of HCV RNA in peripheral blood mononuclear cells and/or hepatocytes in the absence of positive HCV RNA in the serum, although its clinical significance has not been proven. We do not routinely screen patients who are negative for HCV RNA for occult HCV infection in a low-prevalence setting. The prevalence of occult HCV infection has been found to be very low in patients on maintenance hemodialysis in a low-prevalence region [<a href="#rid27">27</a>]. An exception is patients with unexplained impairment of liver function in the absence of serum HCV RNA in high-prevalence units/regions, among whom we may test for occult HCV infection in peripheral blood mononuclear cells [<a href="#rid80">80</a>]. It is reasonable to refer such patients for evaluation of liver disease, similar to those with positive HCV RNA, since occult HCV infection has been proposed but not confirmed to affect viral reactivation and disease progression and the risk of HCV transmission within dialysis units.</p><p class="headingAnchor" id="H1075628418"><span class="h1">EVALUATION OF LIVER DISEASE</span><span class="headingEndMark"> — </span>In general, the evaluation of liver disease in patients with HCV infection on dialysis is similar to that in the general population and is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/15832.html" rel="external">"Patient evaluation and selection for antiviral therapy for chronic hepatitis C virus infection"</a>.)</p><p>However, there are dialysis-specific considerations in the noninvasive staging of hepatic fibrosis:</p><p class="bulletIndent1"><span class="glyph">●</span>Blood tests like the aspartate aminotransferase to platelet ratio index (APRI) or Fibrosis-4 index (FIB-4) score may yield a false negative result in patients on dialysis, as transaminase levels in patients on dialysis tend to fall within the lower end of the range of normal values. (See  <a class="medical medical_review" href="/d/html/1239.html" rel="external">"Noninvasive assessment of hepatic fibrosis: Overview of serologic tests and imaging examinations"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Although imaging such as transient elastography (TE), which uses shear wave imaging to estimate liver stiffness, has been shown to be reasonably accurate for the evaluation of liver fibrosis in patients on hemodialysis [<a href="#rid81">81</a>], TE should be performed postdialysis. Liver stiffness measurements have been shown to decrease significantly after a hemodialysis session, and the decrease is associated with the amount of fluid removed [<a href="#rid82">82-84</a>]. (See  <a class="medical medical_review" href="/d/html/1239.html" rel="external">"Noninvasive assessment of hepatic fibrosis: Overview of serologic tests and imaging examinations"</a>.)</p><p></p><p>When liver biopsy is indicated, end-stage kidney disease (ESKD) does not appear to increase the risk of bleeding with percutaneous biopsy [<a href="#rid85">85</a>]. To decrease the risk of postinterventional bleeding in patients with coagulation disorders and in patients on peritoneal dialysis, a transjugular approach instead of a percutaneous approach can be used [<a href="#rid86">86</a>]. The indications for liver biopsy in patients with hepatitis C are discussed separately. (See  <a class="medical medical_review" href="/d/html/7310.html" rel="external">"Hepatitis C infection in kidney transplant candidates and recipients", section on 'HCV evaluation of transplant candidates'</a> and  <a class="medical medical_review" href="/d/html/15832.html" rel="external">"Patient evaluation and selection for antiviral therapy for chronic hepatitis C virus infection", section on 'Assessment of fibrosis stage'</a>.)</p><p>Among patients with advanced fibrosis and cirrhosis related to HCV, screening for hepatocellular carcinoma (typically with abdominal ultrasound) should be performed every six months. The methods of surveillance are discussed separately. (See  <a class="medical medical_review" href="/d/html/3583.html" rel="external">"Surveillance for hepatocellular carcinoma in adults", section on 'Our approach to surveillance'</a>.)</p><p class="headingAnchor" id="H799424751"><span class="h1">CLINICAL COURSE AND PROGNOSIS</span><span class="headingEndMark"> — </span>The clinical presentation of HCV infection in patients on dialysis is similar to that in the general population; most patients have minimal or no symptoms. (See  <a class="medical medical_review" href="/d/html/3672.html" rel="external">"Clinical manifestations and natural history of chronic hepatitis C virus infection", section on 'Clinical features'</a>.)</p><p>Among patients with chronic HCV infection, the rate of progression of hepatic fibrosis is highly variable and depends on other risk factors for liver disease (eg, HIV or hepatitis B virus [HBV] coinfection, alcohol use, obesity). Many patients may develop only mild hepatic inflammation and fibrosis in their lifetime. Data on the rate of fibrosis progression in patients with HCV and end-stage kidney disease (ESKD) are mostly limited to single-center cross-sectional studies and a few prospective studies with relatively short follow-up and no histologic evaluation [<a href="#rid77">77</a>]. Given the overall lower life expectancy of patients on hemodialysis, complications like decompensated cirrhosis and hepatocellular carcinoma may not have time to develop. Among HCV-seropositive patients who undergo a liver biopsy as part of the evaluation for kidney transplantation, the prevalence of advanced fibrosis and cirrhosis has ranged from 10 to 25 percent [<a href="#rid87">87-89</a>].</p><p>Despite competing comorbidities, HCV infection is independently associated with decreased survival among patients with ESKD [<a href="#rid77">77</a>]. In a 2019 meta-analysis of 23 observational studies and 574,081 patients on dialysis, HCV-seropositive status was associated with a higher risk of death (hazard ratio [HR] 1.26, 95% CI 1.18-1.34) [<a href="#rid90">90</a>]. This and other analyses also demonstrated increased cardiovascular risk among patients on dialysis with HCV infection [<a href="#rid91">91,92</a>], which is consistent with observations in the general population. (See  <a class="medical medical_review" href="/d/html/1854.html" rel="external">"Acute hemodialysis prescription"</a>.)</p><p>Patients with HCV infection who undergo kidney transplantation have decreased mortality compared with patients with HCV infection on dialysis. This issue is discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/7310.html" rel="external">"Hepatitis C infection in kidney transplant candidates and recipients"</a>.)</p><p class="headingAnchor" id="H2211532164"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>Cure of HCV infection prior to the development of decompensated cirrhosis results in decreased all-cause mortality, liver-related death, need for liver transplantation, hepatocellular carcinoma rates, and liver-related complications. Elimination of HCV infection among patients on dialysis also reduces the risk of health care–associated transmission and outbreaks [<a href="#rid93">93-96</a>]. Details regarding the rationale, candidacy, safety, and selection of HCV therapy in patients with kidney function impairment (including those on dialysis) are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/93448.html" rel="external">"Treatment of chronic hepatitis C infection in adults with kidney function impairment"</a>.) </p><p>Considerations for managing HCV infection in patients on dialysis who are kidney transplant candidates are also discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/7310.html" rel="external">"Hepatitis C infection in kidney transplant candidates and recipients"</a>.)</p><p class="headingAnchor" id="H3132500578"><span class="h1">MANAGEMENT OF EXPOSED HEALTH CARE PERSONNEL (NEEDLESTICK INJURY)</span><span class="headingEndMark"> — </span>The reported risk of transmission of HCV from patients with infection to medical staff by needlestick injury ranges from 0 to 10 percent [<a href="#rid97">97-101</a>]. In one study, transmission occurred only from hollow-bore needles and not from any other sharps [<a href="#rid101">101</a>]. (See  <a class="medical medical_review" href="/d/html/3647.html" rel="external">"Prevention of hepatitis B virus and hepatitis C virus infection among health care providers"</a>.)</p><p>Despite the risk, the prevalence of HCV seropositivity among dialysis staff is comparable with that in blood donors. In one study in which 16 percent of dialysis centers in the United States tested staff members for anti-HCV antibodies, among the 6236 staff members tested, the prevalence of anti-HCV antibodies was 2 percent (range 0 to 10 percent in centers with at least 20 staff members) [<a href="#rid21">21</a>].</p><p class="headingAnchor" id="H1702973193"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/113060.html" rel="external">"Society guideline links: Hepatitis C virus infection"</a> and  <a class="medical medical_society_guidelines" href="/d/html/112932.html" rel="external">"Society guideline links: Dialysis"</a>.)</p><p class="headingAnchor" id="H6144511"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology</strong> – The prevalence of hepatitis C virus (HCV) infection is higher among patients on dialysis than in other populations, particularly in resource-limited countries. (See <a class="local">'Introduction'</a> above and <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk factors</strong> – Dialysis-specific risk factors for HCV infection include dialysis vintage, hemodialysis compared with peritoneal dialysis, a high prevalence of HCV infection in the individual dialysis unit, and a low personnel-to-patient ratio in the individual dialysis unit. If patients with HCV viremia are being dialyzed in the same unit as patients without HCV viremia, there is a risk of health care–associated transmission. (See <a class="local">'Risk factors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevention</strong> – Dialysis units should implement and adhere to strict procedures (including universal precautions) aimed at preventing transmission of bloodborne pathogens  (<a class="graphic graphic_table graphicRef97603" href="/d/graphic/97603.html" rel="external">table 1</a>). Patients with HCV infection do not require isolation or the use of dedicated dialysis machines or specific dialysis membranes. Reuse or reprocessing dialyzers does not appear to increase nosocomial transmission of HCV infection, provided infection control measures are employed. (See <a class="local">'Prevention'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Screening and diagnosis</strong> – All patients on dialysis should be screened for HCV infection. Because of the risk of a false-negative anti-HCV antibody in the setting of end-stage kidney disease (ESKD), we generally screen patients on dialysis with anti-HCV antibody and HCV RNA testing concurrently. (See <a class="local">'Screening and diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong> – Decisions to initiate antiviral treatment in patients on dialysis should be undertaken on a case-by-case basis, taking into account the anticipated benefits of HCV therapy, life expectancy, comorbidities, and potential for kidney transplant candidacy. The details regarding rationale, candidacy, safety, and selection of HCV therapy in patients with kidney function impairment (including those on dialysis) are presented separately. (See  <a class="medical medical_review" href="/d/html/93448.html" rel="external">"Treatment of chronic hepatitis C infection in adults with kidney function impairment"</a> and  <a class="medical medical_review" href="/d/html/7310.html" rel="external">"Hepatitis C infection in kidney transplant candidates and recipients"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis</strong> – HCV infection decreases survival among patients with ESKD. (See <a class="local">'Clinical course and prognosis'</a> above.)</p><p></p><p class="headingAnchor" id="H2874414696"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Svetlozar Natov, MD and Brian JG Pereira, MD who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Jadoul M, Bieber BA, Martin P, et al. Prevalence, incidence, and risk factors for hepatitis C virus infection in hemodialysis patients. Kidney Int 2019; 95:939.</a></li><li><a class="nounderline abstract_t">Fissell RB, Bragg-Gresham JL, Woods JD, et al. Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents: the DOPPS. Kidney Int 2004; 65:2335.</a></li><li><a class="nounderline abstract_t">Su Y, Norris JL, Zang C, et al. Incidence of hepatitis C virus infection in patients on hemodialysis: a systematic review and meta-analysis. Hemodial Int 2013; 17:532.</a></li><li><a class="nounderline abstract_t">Finelli L, Miller JT, Tokars JI, et al. National surveillance of dialysis-associated diseases in the United States, 2002. Semin Dial 2005; 18:52.</a></li><li><a class="nounderline abstract_t">de Jesus Rodrigues de Freitas M, Fecury AA, de Almeida MK, et al. Prevalence of hepatitis C virus infection and genotypes in patient with chronic kidney disease undergoing hemodialysis. J Med Virol 2013; 85:1741.</a></li><li><a class="nounderline abstract_t">Vidales-Braz BM, da Silva NM, Lobato R, et al. Detection of hepatitis C virus in patients with terminal renal disease undergoing dialysis in southern Brazil: prevalence, risk factors, genotypes, and viral load dynamics in hemodialysis patients. Virol J 2015; 12:8.</a></li><li><a class="nounderline abstract_t">Couroucé AM, Bouchardeau F, Chauveau P, et al. Hepatitis C virus (HCV) infection in haemodialysed patients: HCV-RNA and anti-HCV antibodies (third-generation assays). Nephrol Dial Transplant 1995; 10:234.</a></li><li><a class="nounderline abstract_t">Sauné K, Kamar N, Miédougé M, et al. Decreased prevalence and incidence of HCV markers in haemodialysis units: a multicentric French survey. Nephrol Dial Transplant 2011; 26:2309.</a></li><li><a class="nounderline abstract_t">Fabrizi F, Lunghi G, Raffaele L, et al. Serologic survey for control of hepatitis C in haemodialysis patients: third-generation assays and analysis of costs. Nephrol Dial Transplant 1997; 12:298.</a></li><li><a class="nounderline abstract_t">Biamino E, Caligaris F, Ferrero S, et al. [Prevalence of anti-HCV antibody positivity and seroconversion incidence in hemodialysis patients]. Minerva Urol Nefrol 1999; 51:53.</a></li><li><a class="nounderline abstract_t">Di Napoli A, Pezzotti P, Di Lallo D, et al. Epidemiology of hepatitis C virus among long-term dialysis patients: a 9-year study in an Italian region. Am J Kidney Dis 2006; 48:629.</a></li><li><a class="nounderline abstract_t">Amiri ZM, Shakib AJ, Toorchi M. Seroprevalence of hepatitis C and risk factors in haemodialysis patients in Guilan, Islamic Republic of Iran. East Mediterr Health J 2005; 11:372.</a></li><li><a class="nounderline abstract_t">Assarehzadegan MA, Shakerinejad G, Noroozkohnejad R, et al. Prevalence of hepatitis C and B infection and HC V genotypes among hemodialysis patients in Khuzestan province, southwest Iran. Saudi J Kidney Dis Transpl 2009; 20:681.</a></li><li><a class="nounderline abstract_t">Othman B, Monem F. Prevalence of antibodies to hepatitis C virus among hemodialysis patients in Damascus, Syria. Infection 2001; 29:262.</a></li><li><a class="nounderline abstract_t">Aman K, Al-Dubai SA, Aman R, et al. Prevalence and associated factors of hepatitis C virus infection among renal disease patients on maintenance hemodialysis in three health centers in Aden, Yemen: a cross sectional study. Saudi J Kidney Dis Transpl 2015; 26:380.</a></li><li><a class="nounderline abstract_t">Selm SB. Prevalence of hepatitis C virus infection among hemodialysis patients in a single center in Yemen. Saudi J Kidney Dis Transpl 2010; 21:1165.</a></li><li><a class="nounderline abstract_t">Khodir SA, Alghateb M, Okasha KM, Shalaby Sel-S. Prevalence of HCV infections among hemodialysis patients in Al Gharbiyah Governorate, Egypt. Arab J Nephrol Transplant 2012; 5:145.</a></li><li><a class="nounderline abstract_t">Lioussfi Z, Errami Z, Radoui A, et al. Viral hepatitis C and B among dialysis patients at the Rabat University Hospital: prevalence and risk factors. Saudi J Kidney Dis Transpl 2014; 25:672.</a></li><li><a class="nounderline abstract_t">Covic A, Iancu L, Apetrei C, et al. Hepatitis virus infection in haemodialysis patients from Moldavia. Nephrol Dial Transplant 1999; 14:40.</a></li><li><a class="nounderline abstract_t">Kamar N, Ribes D, Izopet J, Rostaing L. Treatment of hepatitis C virus infection (HCV) after renal transplantation: implications for HCV-positive dialysis patients awaiting a kidney transplant. Transplantation 2006; 82:853.</a></li><li><a class="nounderline abstract_t">Tokars JI, Miller ER, Alter MJ, Arduino MJ. National surveillance of dialysis associated diseases in the United States, 1995. ASAIO J 1998; 44:98.</a></li><li><a class="nounderline abstract_t">Adane T, Getawa S. The prevalence and associated factors of hepatitis B and C virus in hemodialysis patients in Africa: A systematic review and meta-analysis. PLoS One 2021; 16:e0251570.</a></li><li><a class="nounderline abstract_t">Greeviroj P, Lertussavavivat T, Thongsricome T, et al. The world prevalence, associated risk factors and mortality of hepatitis C virus infection in hemodialysis patients: a meta-analysis. J Nephrol 2022; 35:2269.</a></li><li><a class="nounderline abstract_t">Geerlings W, Tufveson G, Ehrich JH, et al. Report on management of renal failure in Europe, XXIII. Nephrol Dial Transplant 1994; 9 Suppl 1:6.</a></li><li><a class="nounderline abstract_t">Valderrábano F, Jones EH, Mallick NP. Report on management of renal failure in Europe, XXIV, 1993. Nephrol Dial Transplant 1995; 10 Suppl 5:1.</a></li><li><a class="nounderline abstract_t">Jadoul M, Poignet JL, Geddes C, et al. The changing epidemiology of hepatitis C virus (HCV) infection in haemodialysis: European multicentre study. Nephrol Dial Transplant 2004; 19:904.</a></li><li><a class="nounderline abstract_t">Baid-Agrawal S, Schindler R, Reinke P, et al. Prevalence of occult hepatitis C infection in chronic hemodialysis and kidney transplant patients. J Hepatol 2014; 60:928.</a></li><li><a class="nounderline abstract_t">Espinosa M, Martn-Malo A, Ojeda R, et al. Marked reduction in the prevalence of hepatitis C virus infection in hemodialysis patients: causes and consequences. Am J Kidney Dis 2004; 43:685.</a></li><li><a class="nounderline abstract_t">Fabrizi F, Messa P. Transmission of hepatitis C virus in dialysis units: a systematic review of reports on outbreaks. Int J Artif Organs 2015; 38:471.</a></li><li><a class="nounderline abstract_t">Khan S, Attaullah S, Ali I, et al. Rising burden of Hepatitis C Virus in hemodialysis patients. Virol J 2011; 8:438.</a></li><li><a class="nounderline abstract_t">Natov SN, Lau JY, Bouthot BA, et al. Serologic and virologic profiles of hepatitis C infection in renal transplant candidates. New England Organ Bank Hepatitis C Study Group. Am J Kidney Dis 1998; 31:920.</a></li><li><a class="nounderline abstract_t">Cai G, Zheng H, Luo L, et al. Factors Correlating to the Development of Hepatitis C Virus Infection in Hemodialysis Patients-Findings Mainly from Asiatic Populations: A Systematic Review and Meta-Analysis. Int J Environ Res Public Health 2019; 16.</a></li><li><a class="nounderline abstract_t">Pereira BJ, Levey AS. Hepatitis C virus infection in dialysis and renal transplantation. Kidney Int 1997; 51:981.</a></li><li><a class="nounderline abstract_t">Cendoroglo Neto M, Draibe SA, Silva AE, et al. Incidence of and risk factors for hepatitis B virus and hepatitis C virus infection among haemodialysis and CAPD patients: evidence for environmental transmission. Nephrol Dial Transplant 1995; 10:240.</a></li><li><a class="nounderline abstract_t">Weinstein T, Tur-Kaspa R, Chagnac A, et al. Hepatitis C infection in dialysis patients in Israel. Isr Med Assoc J 2001; 3:174.</a></li><li><a class="nounderline abstract_t">Pascual J, Teruel JL, Liaño F, Ortuño J. Home hemodialysis protects against hepatitis C virus transmission. Nephron 1993; 64:314.</a></li><li><a class="nounderline abstract_t">dos Santos JP, Loureiro A, Cendoroglo Neto M, Pereira BJ. Impact of dialysis room and reuse strategies on the incidence of hepatitis C virus infection in haemodialysis units. Nephrol Dial Transplant 1996; 11:2017.</a></li><li><a class="nounderline abstract_t">Jadoul M, Cornu C, van Ypersele de Strihou C. Incidence and risk factors for hepatitis C seroconversion in hemodialysis: a prospective study. The UCL Collaborative Group. Kidney Int 1993; 44:1322.</a></li><li><a class="nounderline abstract_t">Petrosillo N, Gilli P, Serraino D, et al. Prevalence of infected patients and understaffing have a role in hepatitis C virus transmission in dialysis. Am J Kidney Dis 2001; 37:1004.</a></li><li><a class="nounderline abstract_t">Stuyver L, Claeys H, Wyseur A, et al. Hepatitis C virus in a hemodialysis unit: molecular evidence for nosocomial transmission. Kidney Int 1996; 49:889.</a></li><li><a class="nounderline abstract_t">Halfon P, Roubicek C, Gerolami V, et al. Use of phylogenetic analysis of hepatitis C virus (HCV) hypervariable region 1 sequences to trace an outbreak of HCV in an autodialysis unit. J Clin Microbiol 2002; 40:1541.</a></li><li><a class="nounderline abstract_t">Grethe S, Gemsa F, Monazahian M, et al. Molecular epidemiology of an outbreak of HCV in a hemodialysis unit: direct sequencing of HCV-HVR1 as an appropriate tool for phylogenetic analysis. J Med Virol 2000; 60:152.</a></li><li><a class="nounderline abstract_t">Olmer M, Bouchouareb D, Zandotti C, et al. Transmission of the hepatitis C virus in an hemodialysis unit: evidence for nosocomial infection. Clin Nephrol 1997; 47:263.</a></li><li><a class="nounderline abstract_t">Sypsa V, Psichogiou M, Katsoulidou A, et al. Incidence and patterns of hepatitis C virus seroconversion in a cohort of hemodialysis patients. Am J Kidney Dis 2005; 45:334.</a></li><li><a class="nounderline abstract_t">Bergman S, Accortt N, Turner A, Glaze J. Hepatitis C infection is acquired pre-ESRD. Am J Kidney Dis 2005; 45:684.</a></li><li><a class="nounderline abstract_t">DuBois DB, Gretch D, dela Rosa C, et al. Quantitation of hepatitis C viral RNA in sera of hemodialysis patients: gender-related differences in viral load. Am J Kidney Dis 1994; 24:795.</a></li><li><a class="nounderline abstract_t">Jeffers LJ, Perez GO, de Medina MD, et al. Hepatitis C infection in two urban hemodialysis units. Kidney Int 1990; 38:320.</a></li><li><a class="nounderline abstract_t">Alter MJ, Margolis HS, Krawczynski K, et al. The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team. N Engl J Med 1992; 327:1899.</a></li><li><a class="nounderline abstract_t">Recommendations for preventing transmission of infections among chronic hemodialysis patients. MMWR Recomm Rep 2001; 50:1.</a></li><li><a class="nounderline abstract_t">Kidney Disease: Improving Global Outcomes (KDIGO) Hepatitis C Work Group. KDIGO 2022 Clinical Practice Guideline FOR the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease. Kidney Int 2022; 102:S129.</a></li><li><a class="nounderline abstract_t">Jadoul M, Cornu C, van Ypersele de Strihou C. Universal precautions prevent hepatitis C virus transmission: a 54 month follow-up of the Belgian Multicenter Study. The Universitaires Cliniques St-Luc (UCL) Collaborative Group. Kidney Int 1998; 53:1022.</a></li><li><a class="nounderline abstract_t">Jadoul M, Fabrizi F. What are the management issues for hepatitis C in dialysis patients?: epidemiology and prevention of hepatitis C virus transmission in the hemodialysis setting. Semin Dial 2014; 27:449.</a></li><li><a class="nounderline abstract_t">Okuda K, Hayashi H, Kobayashi S, Irie Y. Mode of hepatitis C infection not associated with blood transfusion among chronic hemodialysis patients. J Hepatol 1995; 23:28.</a></li><li><a class="nounderline abstract_t">Gilli P, Moretti M, Soffritti S, et al. Non-A, non-B hepatitis and anti-HCV antibodies in dialysis patients. Int J Artif Organs 1990; 13:737.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Hepatitis C virus transmission at an outpatient hemodialysis unit--New York, 2001-2008. MMWR Morb Mortal Wkly Rep 2009; 58:189.</a></li><li><a class="nounderline abstract_t">Alfurayh O, Sabeel A, Al Ahdal MN, et al. Hand contamination with hepatitis C virus in staff looking after hepatitis C-positive hemodialysis patients. Am J Nephrol 2000; 20:103.</a></li><li><a class="nounderline abstract_t">Niu MT, Alter MJ, Kristensen C, Margolis HS. Outbreak of hemodialysis-associated non-A, non-B hepatitis and correlation with antibody to hepatitis C virus. Am J Kidney Dis 1992; 19:345.</a></li><li><a class="nounderline abstract_t">Garcia-Valdescasas J, Bernal MC, Cerezo S, et al. Strategies to reduce the transmission of HCV infection in hemodialysis (HD) units (abstract). J Am Soc Nephrol 1993; 4:347.</a></li><li><a class="nounderline abstract_t">Castelnovo C, Sampietro M, De Vecchi A, et al. Diffusion of HCV through peritoneal membrane in HCV positive patients treated with continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant 1997; 12:978.</a></li><li><a class="nounderline abstract_t">Brugnano R, Francisci D, Quintaliani G, et al. Antibodies against hepatitis C virus in hemodialysis patients in the central Italian region of Umbria: evaluation of some risk factors. Nephron 1992; 61:263.</a></li><li><a class="nounderline abstract_t">Mitwalli A, al-Mohaya S, al Wakeel J, et al. Hepatitis C in chronic renal failure patients. Am J Nephrol 1992; 12:288.</a></li><li><a class="nounderline abstract_t">Rais-Jalali G, Khajehdehi P. Anti-HCV seropositivity among haemodialysis patients of Iranian origin. Nephrol Dial Transplant 1999; 14:2055.</a></li><li><a class="nounderline abstract_t">Vagelli G, Calabrese G, Guaschino R, Gonella M. Effect of HCV+ patients isolation on HCV infection incidence in a dialysis unit. Nephrol Dial Transplant 1992; 7:1070.</a></li><li><a class="nounderline abstract_t">Calabrese G, Vagelli G, Guaschino R, Gonella M. Transmission of anti-HCV within the household of haemodialysis patients. Lancet 1991; 338:1466.</a></li><li><a class="nounderline abstract_t">Taskapan H, Oymak O, Dogukan A, Utas C. Patient to patient transmission of hepatitis C virus in hemodialysis units. Clin Nephrol 2001; 55:477.</a></li><li><a class="nounderline abstract_t">Hubmann R, Zazgornik J, Gabriel C, et al. Hepatitis C virus--does it penetrate the haemodialysis membrane? PCR analysis of haemodialysis ultrafiltrate and whole blood. Nephrol Dial Transplant 1995; 10:541.</a></li><li><a class="nounderline abstract_t">Caramelo C, Navas S, Alberola ML, et al. Evidence against transmission of hepatitis C virus through hemodialysis ultrafiltrate and peritoneal fluid. Nephron 1994; 66:470.</a></li><li><a class="nounderline abstract_t">Noiri E, Nakao A, Oya A, et al. Hepatitis C virus in blood and dialysate in hemodialysis. Am J Kidney Dis 2001; 37:38.</a></li><li><a class="nounderline abstract_t">Lombardi M, Cerrai T, Dattolo P, et al. Is the dialysis membrane a safe barrier against HCV infection? Nephrol Dial Transplant 1995; 10:578.</a></li><li><a class="nounderline abstract_t">Froio N, Nicastri E, Comandini UV, et al. Contamination by hepatitis B and C viruses in the dialysis setting. Am J Kidney Dis 2003; 42:546.</a></li><li><a class="nounderline abstract_t">Taal MW, van Zyl-Smit R. Hepatitis C virus infection in chronic haemodialysis patients--relationship to blood transfusions and dialyser re-use. S Afr Med J 2000; 90:621.</a></li><li><a class="nounderline abstract_t">El-Sherif A, Elbahrawy A, Aboelfotoh A, et al. High false-negative rate of anti-HCV among Egyptian patients on regular hemodialysis. Hemodial Int 2012; 16:420.</a></li><li><a class="nounderline abstract_t">Dzekova-Vidimliski P, Severova-Andreevska G, Trajceska L, et al. Aminotransferase activity as a poor predictor of liver disease progression in dialysis patients with chronic hepatitis C. Bratisl Lek Listy 2011; 112:568.</a></li><li><a class="nounderline abstract_t">Sterling RK, Sanyal AJ, Luketic VA, et al. Chronic hepatitis C infection in patients with end stage renal disease: characterization of liver histology and viral load in patients awaiting renal transplantation. Am J Gastroenterol 1999; 94:3576.</a></li><li><a class="nounderline abstract_t">Wolf PL, Williams D, Coplon N, Coulson AS. Low aspartate transaminase activity in serum of patients undergoing chronic hemodialysis. Clin Chem 1972; 18:567.</a></li><li><a class="nounderline abstract_t">Fabrizi F, Martin P, Dixit V, et al. Acquisition of hepatitis C virus in hemodialysis patients: a prospective study by branched DNA signal amplification assay. Am J Kidney Dis 1998; 31:647.</a></li><li><a class="nounderline abstract_t">Baid-Agrawal S, Pascual M, Moradpour D, et al. Hepatitis C virus infection in haemodialysis and kidney transplant patients. Rev Med Virol 2008; 18:97.</a></li><li><a class="nounderline abstract_t">Wong XZ, Amirah A, Gan CC, et al. Hepatitis C virus core antigen as alternative diagnostic algorithm for active hepatitis C virus infection among haemodialysis population: Cost implications. Nephrology (Carlton) 2021; 26:463.</a></li><li><a class="nounderline abstract_t">Ponnuvel S, Fletcher GJ, Anantharam R, et al. Clinical utility of hepatitis C virus core antigen (HCVcAg) assay to identify active HCV infection in hemodialysis and renal transplant patients. PLoS One 2021; 16:e0250263.</a></li><li><a class="nounderline abstract_t">Barril G, Castillo I, Arenas MD, et al. Occult hepatitis C virus infection among hemodialysis patients. J Am Soc Nephrol 2008; 19:2288.</a></li><li><a class="nounderline abstract_t">Liu CH, Liang CC, Huang KW, et al. Transient elastography to assess hepatic fibrosis in hemodialysis chronic hepatitis C patients. Clin J Am Soc Nephrol 2011; 6:1057.</a></li><li><a class="nounderline abstract_t">Khunpakdee N, Jayanama K, Kaewdoung P, et al. Transient Elastography in End-Stage Renal Disease Patients on Hemodialysis: The Effect of Net Fluid Withdrawal. Blood Purif 2015; 40:256.</a></li><li><a class="nounderline abstract_t">Taneja S, Borkakoty A, Rathi S, et al. Assessment of Liver Fibrosis by Transient Elastography Should Be Done After Hemodialysis in End Stage Renal Disease Patients with Liver Disease. Dig Dis Sci 2017; 62:3186.</a></li><li><a class="nounderline abstract_t">Zjacic Puljiz D, Mestrovic A, Zaja I, et al. Impact of hemodialysis on liver stiffness measured with real-time two-dimensional shear wave elastography. Wien Klin Wochenschr 2021; 133:96.</a></li><li><a class="nounderline abstract_t">Pawa S, Ehrinpreis M, Mutchnick M, et al. Percutaneous liver biopsy is safe in chronic hepatitis C patients with end-stage renal disease. Clin Gastroenterol Hepatol 2007; 5:1316.</a></li><li><a class="nounderline abstract_t">Ahmad A, Hasan F, Abdeen S, et al. Transjugular liver biopsy in patients with end-stage renal disease. J Vasc Interv Radiol 2004; 15:257.</a></li><li><a class="nounderline abstract_t">Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney Int Suppl 2008; :S1.</a></li><li><a class="nounderline abstract_t">Martin P, Carter D, Fabrizi F, et al. Histopathological features of hepatitis C in renal transplant candidates [see comment]. Transplantation 2000; 69:1479.</a></li><li><a class="nounderline abstract_t">Roth D, Gaynor JJ, Reddy KR, et al. Effect of kidney transplantation on outcomes among patients with hepatitis C. J Am Soc Nephrol 2011; 22:1152.</a></li><li><a class="nounderline abstract_t">Fabrizi F, Dixit V, Messa P. Hepatitis C virus and mortality among patients on dialysis: A systematic review and meta-analysis. Clin Res Hepatol Gastroenterol 2019; 43:244.</a></li><li><a class="nounderline abstract_t">Sawinski D, Forde KA, Lo Re V 3rd, et al. Mortality and Kidney Transplantation Outcomes Among Hepatitis C Virus-Seropositive Maintenance Dialysis Patients: A Retrospective Cohort Study. Am J Kidney Dis 2019; 73:815.</a></li><li><a class="nounderline abstract_t">Fabrizi F, Dixit V, Messa P. Impact of hepatitis C on survival in dialysis patients: a link with cardiovascular mortality? J Viral Hepat 2012; 19:601.</a></li><li><a class="nounderline abstract_t">Rajasekaran A, Franco RA, Overton ET, et al. Updated Pathway to Micro-elimination of Hepatitis C Virus in the Hemodialysis Population. Kidney Int Rep 2021; 6:1788.</a></li><li><a class="nounderline abstract_t">Yu ML, Huang CF, Wei YJ, et al. Establishment of an outreach, grouping healthcare system to achieve microelimination of HCV for uremic patients in haemodialysis centres (ERASE-C). Gut 2021; 70:2349.</a></li><li><a class="nounderline abstract_t">Huang CF, Chiu YW, Yu ML. Patient-centered outreach treatment toward micro-elimination of hepatitis C virus infection in hemodialysis patients. Kidney Int 2020; 97:421.</a></li><li><a class="nounderline abstract_t">Hu TH, Su WW, Yang CC, et al. Elimination of Hepatitis C Virus in a Dialysis Population: A Collaborative Care Model in Taiwan. Am J Kidney Dis 2021; 78:511.</a></li><li><a class="nounderline abstract_t">Kiyosawa K, Sodeyama T, Tanaka E, et al. Hepatitis C in hospital employees with needlestick injuries. Ann Intern Med 1991; 115:367.</a></li><li><a class="nounderline abstract_t">Mitsui T, Iwano K, Masuko K, et al. Hepatitis C virus infection in medical personnel after needlestick accident. Hepatology 1992; 16:1109.</a></li><li><a class="nounderline abstract_t">Alter MJ. The epidemiology of acute and chronic hepatitis C. Clin Liver Dis 1997; 1:559.</a></li><li><a class="nounderline abstract_t">Lanphear BP, Linnemann CC Jr, Cannon CG, et al. Hepatitis C virus infection in healthcare workers: risk of exposure and infection. Infect Control Hosp Epidemiol 1994; 15:745.</a></li><li><a class="nounderline abstract_t">Puro V, Petrosillo N, Ippolito G. Risk of hepatitis C seroconversion after occupational exposures in health care workers. Italian Study Group on Occupational Risk of HIV and Other Bloodborne Infections. Am J Infect Control 1995; 23:273.</a></li></ol></div><div id="topicVersionRevision">Topic 1861 Version 36.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30904068" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Prevalence, incidence, and risk factors for hepatitis C virus infection in hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15149347" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents: the DOPPS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23072424" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Incidence of hepatitis C virus infection in patients on hemodialysis: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15663766" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : National surveillance of dialysis-associated diseases in the United States, 2002.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23852735" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Prevalence of hepatitis C virus infection and genotypes in patient with chronic kidney disease undergoing hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25644891" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Detection of hepatitis C virus in patients with terminal renal disease undergoing dialysis in southern Brazil: prevalence, risk factors, genotypes, and viral load dynamics in hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7538650" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Hepatitis C virus (HCV) infection in haemodialysed patients: HCV-RNA and anti-HCV antibodies (third-generation assays).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21097646" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Decreased prevalence and incidence of HCV markers in haemodialysis units: a multicentric French survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9132649" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Serologic survey for control of hepatitis C in haemodialysis patients: third-generation assays and analysis of costs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10429410" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : [Prevalence of anti-HCV antibody positivity and seroconversion incidence in hemodialysis patients].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16997059" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Epidemiology of hepatitis C virus among long-term dialysis patients: a 9-year study in an Italian region.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16602456" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Seroprevalence of hepatitis C and risk factors in haemodialysis patients in Guilan, Islamic Republic of Iran.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19587521" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Prevalence of hepatitis C and B infection and HC V genotypes among hemodialysis patients in Khuzestan province, southwest Iran.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11688903" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Prevalence of antibodies to hepatitis C virus among hemodialysis patients in Damascus, Syria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25758898" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Prevalence and associated factors of hepatitis C virus infection among renal disease patients on maintenance hemodialysis in three health centers in Aden, Yemen: a cross sectional study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21060200" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Prevalence of hepatitis C virus infection among hemodialysis patients in a single center in Yemen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22967252" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Prevalence of HCV infections among hemodialysis patients in Al Gharbiyah Governorate, Egypt.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24821177" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Viral hepatitis C and B among dialysis patients at the Rabat University Hospital: prevalence and risk factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10052474" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Hepatitis virus infection in haemodialysis patients from Moldavia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17038897" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Treatment of hepatitis C virus infection (HCV) after renal transplantation: implications for HCV-positive dialysis patients awaiting a kidney transplant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9466509" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : National surveillance of dialysis associated diseases in the United States, 1995.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34157037" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : The prevalence and associated factors of hepatitis B and C virus in hemodialysis patients in Africa: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36383211" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : The world prevalence, associated risk factors and mortality of hepatitis C virus infection in hemodialysis patients: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8008230" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Report on management of renal failure in Europe, XXIII.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7478150" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Report on management of renal failure in Europe, XXIV, 1993.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15031348" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : The changing epidemiology of hepatitis C virus (HCV) infection in haemodialysis: European multicentre study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24447875" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Prevalence of occult hepatitis C infection in chronic hemodialysis and kidney transplant patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15042545" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Marked reduction in the prevalence of hepatitis C virus infection in hemodialysis patients: causes and consequences.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26449566" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Transmission of hepatitis C virus in dialysis units: a systematic review of reports on outbreaks.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21920054" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Rising burden of Hepatitis C Virus in hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9631834" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Serologic and virologic profiles of hepatitis C infection in renal transplant candidates. New England Organ Bank Hepatitis C Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31022900" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Factors Correlating to the Development of Hepatitis C Virus Infection in Hemodialysis Patients-Findings Mainly from Asiatic Populations: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9083262" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Hepatitis C virus infection in dialysis and renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7538651" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Incidence of and risk factors for hepatitis B virus and hepatitis C virus infection among haemodialysis and CAPD patients: evidence for environmental transmission.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11303373" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Hepatitis C infection in dialysis patients in Israel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7686638" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Home hemodialysis protects against hepatitis C virus transmission.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8918716" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Impact of dialysis room and reuse strategies on the incidence of hepatitis C virus infection in haemodialysis units.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7508005" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Incidence and risk factors for hepatitis C seroconversion in hemodialysis: a prospective study. The UCL Collaborative Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11325683" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Prevalence of infected patients and understaffing have a role in hepatitis C virus transmission in dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8648934" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Hepatitis C virus in a hemodialysis unit: molecular evidence for nosocomial transmission.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11923392" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Use of phylogenetic analysis of hepatitis C virus (HCV) hypervariable region 1 sequences to trace an outbreak of HCV in an autodialysis unit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10596014" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Molecular epidemiology of an outbreak of HCV in a hemodialysis unit: direct sequencing of HCV-HVR1 as an appropriate tool for phylogenetic analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9128794" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Transmission of the hepatitis C virus in an hemodialysis unit: evidence for nosocomial infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15685512" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Incidence and patterns of hepatitis C virus seroconversion in a cohort of hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15806471" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Hepatitis C infection is acquired pre-ESRD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7977321" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Quantitation of hepatitis C viral RNA in sera of hemodialysis patients: gender-related differences in viral load.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2119469" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Hepatitis C infection in two urban hemodialysis units.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1280771" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11349873" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Recommendations for preventing transmission of infections among chronic hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36410841" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : KDIGO 2022 Clinical Practice Guideline FOR the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9551413" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Universal precautions prevent hepatitis C virus transmission: a 54 month follow-up of the Belgian Multicenter Study. The Universitaires Cliniques St-Luc (UCL) Collaborative Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25204877" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : What are the management issues for hepatitis C in dialysis patients?: epidemiology and prevention of hepatitis C virus transmission in the hemodialysis setting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8530806" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Mode of hepatitis C infection not associated with blood transfusion among chronic hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2128485" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Non-A, non-B hepatitis and anti-HCV antibodies in dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19265779" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Hepatitis C virus transmission at an outpatient hemodialysis unit--New York, 2001-2008.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10773609" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Hand contamination with hepatitis C virus in staff looking after hepatitis C-positive hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1562024" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Outbreak of hemodialysis-associated non-A, non-B hepatitis and correlation with antibody to hepatitis C virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Strategies to reduce the transmission of HCV infection in hemodialysis (HD) units (abstract)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9175053" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Diffusion of HCV through peritoneal membrane in HCV positive patients treated with continuous ambulatory peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1323768" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Antibodies against hepatitis C virus in hemodialysis patients in the central Italian region of Umbria: evaluation of some risk factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1336933" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Hepatitis C in chronic renal failure patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10462312" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Anti-HCV seropositivity among haemodialysis patients of Iranian origin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1331887" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Effect of HCV+ patients isolation on HCV infection incidence in a dialysis unit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1683456" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Transmission of anti-HCV within the household of haemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11434360" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Patient to patient transmission of hepatitis C virus in hemodialysis units.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7623999" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Hepatitis C virus--does it penetrate the haemodialysis membrane? PCR analysis of haemodialysis ultrafiltrate and whole blood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7517019" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Evidence against transmission of hepatitis C virus through hemodialysis ultrafiltrate and peritoneal fluid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11136165" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Hepatitis C virus in blood and dialysate in hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7624011" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Is the dialysis membrane a safe barrier against HCV infection?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12955683" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Contamination by hepatitis B and C viruses in the dialysis setting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10918894" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Hepatitis C virus infection in chronic haemodialysis patients--relationship to blood transfusions and dialyser re-use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22360424" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : High false-negative rate of anti-HCV among Egyptian patients on regular hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21954541" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Aminotransferase activity as a poor predictor of liver disease progression in dialysis patients with chronic hepatitis C.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10606322" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Chronic hepatitis C infection in patients with end stage renal disease: characterization of liver histology and viral load in patients awaiting renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5026769" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Low aspartate transaminase activity in serum of patients undergoing chronic hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9531181" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Acquisition of hepatitis C virus in hemodialysis patients: a prospective study by branched DNA signal amplification assay.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18064722" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Hepatitis C virus infection in haemodialysis and kidney transplant patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33580732" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Hepatitis C virus core antigen as alternative diagnostic algorithm for active hepatitis C virus infection among haemodialysis population: Cost implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33886631" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Clinical utility of hepatitis C virus core antigen (HCVcAg) assay to identify active HCV infection in hemodialysis and renal transplant patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18684893" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Occult hepatitis C virus infection among hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21393486" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Transient elastography to assess hepatic fibrosis in hemodialysis chronic hepatitis C patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26430774" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Transient Elastography in End-Stage Renal Disease Patients on Hemodialysis: The Effect of Net Fluid Withdrawal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28948504" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Assessment of Liver Fibrosis by Transient Elastography Should Be Done After Hemodialysis in End Stage Renal Disease Patients with Liver Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31781940" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Impact of hemodialysis on liver stiffness measured with real-time two-dimensional shear wave elastography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17904916" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Percutaneous liver biopsy is safe in chronic hepatitis C patients with end-stage renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15028810" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Transjugular liver biopsy in patients with end-stage renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18382440" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10798774" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Histopathological features of hepatitis C in renal transplant candidates [see comment].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21546575" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Effect of kidney transplantation on outcomes among patients with hepatitis C.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30910601" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Hepatitis C virus and mortality among patients on dialysis: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30704882" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Mortality and Kidney Transplantation Outcomes Among Hepatitis C Virus-Seropositive Maintenance Dialysis Patients: A Retrospective Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22863263" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Impact of hepatitis C on survival in dialysis patients: a link with cardiovascular mortality?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34307975" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Updated Pathway to Micro-elimination of Hepatitis C Virus in the Hemodialysis Population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33303567" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Establishment of an outreach, grouping healthcare system to achieve microelimination of HCV for uremic patients in haemodialysis centres (ERASE-C).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31980077" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Patient-centered outreach treatment toward micro-elimination of hepatitis C virus infection in hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33940114" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Elimination of Hepatitis C Virus in a Dialysis Population: A Collaborative Care Model in Taiwan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1907441" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Hepatitis C in hospital employees with needlestick injuries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1427651" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Hepatitis C virus infection in medical personnel after needlestick accident.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15560058" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : The epidemiology of acute and chronic hepatitis C.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7534324" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Hepatitis C virus infection in healthcare workers: risk of exposure and infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8585637" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Risk of hepatitis C seroconversion after occupational exposures in health care workers. Italian Study Group on Occupational Risk of HIV and Other Bloodborne Infections.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
